Skip to main content

Izumi Raquel E.'s Form 4 filing

Vincerx Pharma, Inc. (VINC) · filed Aug 10, 2023

Accession no.
0000950170-23-041513
Filed
Aug 10, 2023
Trade date
Aug 9-10, 2023
Filing delay
1 day
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions. Open-market purchases total $14.9K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Izumi Raquel E.CIK 0001832553Director, Officer (See Remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 9, 2023Common StockPPurchaseAcquired+13,036$0.90F1+$11,732.481,774Indirect
Aug 10, 2023Common StockPPurchaseAcquired+3,440$0.93F2+$3,199.285,214Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Represents a weighted average purchase price. Actual purchase prices ranged from $0.90 to $0.94 per share. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares purchased within the range indicated.

Referenced by the price of 1 transaction in Table I.

F2

Represents actual price

Referenced by the price of 1 transaction in Table I.

Remarks

President and Chief Operations Officer

Read the full filing on SEC EDGAR (opens in a new tab)